PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
出版年份 2017 全文链接
标题
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
作者
关键词
-
出版物
ONCOGENE
Volume 37, Issue 3, Pages 341-351
出版商
Springer Nature
发表日期
2017-09-25
DOI
10.1038/onc.2017.326
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes
- (2016) Dong Wang et al. GYNECOLOGIC ONCOLOGY
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- SIRT7 is a histone desuccinylase that functionally links to chromatin compaction and genome stability
- (2016) Lei Li et al. Nature Communications
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
- (2016) Dong Wang et al. Oncotarget
- Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
- (2016) Robert J. Cardnell et al. PLoS One
- mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
- (2015) W. Mo et al. CLINICAL CANCER RESEARCH
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
- (2014) Aki Miyasaka et al. BMC CANCER
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition
- (2014) E. Gonzalez-Billalabeitia et al. Cancer Discovery
- A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition
- (2013) H. Cheng et al. CANCER RESEARCH
- PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
- (2013) B. Weigelt et al. CLINICAL CANCER RESEARCH
- Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition In Vivo
- (2013) D. M. Janzen et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress
- (2013) C. Bassi et al. SCIENCE
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Evolutionary Pathways in BRCA1-Associated Breast Tumors
- (2012) Filipe C. Martins et al. Cancer Discovery
- PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
- (2011) M. Fraser et al. CLINICAL CANCER RESEARCH
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
- (2011) Martin D. Forster et al. Nature Reviews Clinical Oncology
- Emerging therapeutic targets in endometrial cancer
- (2011) Konstantin J. Dedes et al. Nature Reviews Clinical Oncology
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
- (2011) Lydia W.T. Cheung et al. Cancer Discovery
- PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) B. McEllin et al. CANCER RESEARCH
- PARP inhibition in BRCA-mutated breast and ovarian cancers
- (2010) Stephen L Chan et al. LANCET
- PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
- (2010) K. J. Dedes et al. Science Translational Medicine
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now